Ascendis Pharma A/S (NASDAQ:ASND) Stock Position Raised by Rice Hall James & Associates LLC

Rice Hall James & Associates LLC raised its stake in Ascendis Pharma A/S (NASDAQ:ASND) by 5.9% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 160,614 shares of the biotechnology company’s stock after acquiring an additional 8,958 shares during the period. Ascendis Pharma A/S accounts for about 1.3% of Rice Hall James & Associates LLC’s investment portfolio, making the stock its 22nd biggest holding. Rice Hall James & Associates LLC owned about 0.28% of Ascendis Pharma A/S worth $23,981,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently made changes to their positions in the company. Signaturefd LLC lifted its stake in Ascendis Pharma A/S by 13.2% in the third quarter. Signaturefd LLC now owns 686 shares of the biotechnology company’s stock valued at $102,000 after buying an additional 80 shares during the last quarter. Bessemer Group Inc. grew its position in Ascendis Pharma A/S by 61.0% in the 1st quarter. Bessemer Group Inc. now owns 876 shares of the biotechnology company’s stock worth $132,000 after purchasing an additional 332 shares during the last quarter. Searle & CO. acquired a new stake in shares of Ascendis Pharma A/S in the second quarter valued at approximately $205,000. Rhumbline Advisers raised its holdings in shares of Ascendis Pharma A/S by 10.3% during the second quarter. Rhumbline Advisers now owns 1,533 shares of the biotechnology company’s stock valued at $209,000 after buying an additional 143 shares during the last quarter. Finally, SG Americas Securities LLC acquired a new position in shares of Ascendis Pharma A/S during the first quarter worth approximately $288,000.

Wall Street Analyst Weigh In

Several analysts have weighed in on ASND shares. The Goldman Sachs Group lifted their target price on Ascendis Pharma A/S from $180.00 to $200.00 and gave the company a “buy” rating in a research note on Tuesday, September 17th. TD Cowen raised their target price on shares of Ascendis Pharma A/S from $157.00 to $160.00 and gave the company a “buy” rating in a research note on Monday, October 21st. StockNews.com raised shares of Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research note on Thursday, September 5th. Bank of America boosted their price target on shares of Ascendis Pharma A/S from $175.00 to $191.00 and gave the stock a “buy” rating in a research report on Monday, September 23rd. Finally, Wells Fargo & Company raised their price objective on shares of Ascendis Pharma A/S from $264.00 to $289.00 and gave the company an “overweight” rating in a research report on Tuesday, September 17th. Two analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $195.92.

Ascendis Pharma A/S Trading Up 0.0 %

NASDAQ:ASND opened at $122.82 on Friday. The firm has a market capitalization of $7.45 billion, a PE ratio of -13.19 and a beta of 0.64. Ascendis Pharma A/S has a 1 year low of $86.54 and a 1 year high of $161.00. The firm’s fifty day simple moving average is $134.04 and its 200 day simple moving average is $133.89.

Ascendis Pharma A/S (NASDAQ:ASND) last posted its quarterly earnings data on Tuesday, September 3rd. The biotechnology company reported ($2.05) EPS for the quarter, missing analysts’ consensus estimates of ($1.54) by ($0.51). The firm had revenue of $38.75 million during the quarter, compared to analyst estimates of $94.74 million. As a group, analysts anticipate that Ascendis Pharma A/S will post -7.2 EPS for the current fiscal year.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.